[go: up one dir, main page]

IL139220A0 - Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection - Google Patents

Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection

Info

Publication number
IL139220A0
IL139220A0 IL13922099A IL13922099A IL139220A0 IL 139220 A0 IL139220 A0 IL 139220A0 IL 13922099 A IL13922099 A IL 13922099A IL 13922099 A IL13922099 A IL 13922099A IL 139220 A0 IL139220 A0 IL 139220A0
Authority
IL
Israel
Prior art keywords
ribavirin
infection
combination therapy
interferon alpha
chronic hepatitis
Prior art date
Application number
IL13922099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139220(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL139220A0 publication Critical patent/IL139220A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL13922099A 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection IL139220A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
IL139220A0 true IL139220A0 (en) 2001-11-25

Family

ID=22151354

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13922099A IL139220A0 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Country Status (22)

Country Link
EP (3) EP2305287A1 (xx)
JP (2) JP5281726B2 (xx)
KR (1) KR100694345B1 (xx)
CN (1) CN1230198C (xx)
AR (1) AR019551A1 (xx)
AT (1) ATE216591T1 (xx)
AU (2) AU766597B2 (xx)
BR (1) BR9910505A (xx)
CA (1) CA2331823A1 (xx)
CZ (1) CZ300540B6 (xx)
DE (1) DE69901321T2 (xx)
DK (1) DK0956861T3 (xx)
ES (1) ES2172288T3 (xx)
HU (1) HU230432B1 (xx)
IL (3) IL139220A0 (xx)
MY (1) MY129244A (xx)
NO (1) NO330715B1 (xx)
NZ (1) NZ507621A (xx)
PT (1) PT956861E (xx)
SK (1) SK288038B6 (xx)
TW (1) TWI277424B (xx)
WO (1) WO1999059621A1 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
HK1049944A1 (zh) * 1999-12-23 2003-06-06 Icn Pharmaceuticals, Inc. L-核苷、l-核苷酸及其类似物的组合物和治疗方法
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
BR0114636A (pt) * 2000-10-18 2004-02-10 Schering Corp Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
AU2002365436B8 (en) * 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CN1980678A (zh) * 2003-03-28 2007-06-13 法莫赛特股份有限公司 治疗黄病毒感染的化合物
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CA2521650A1 (en) * 2003-04-17 2004-10-28 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
PL2604620T5 (pl) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
AU2007204963B2 (en) * 2006-01-09 2012-09-27 Romark Laboratories, L.C. Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
CN103635196B (zh) * 2011-03-02 2019-05-07 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物、治疗方法和诊断方法
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2176229C (en) 1993-11-10 2003-05-27 Carl W. Gilbert Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1999008729A1 (en) 1997-08-13 1999-02-25 Boston Scientific Limited Loading and release of water-insoluble drugs
DE69810822T2 (de) * 1997-09-21 2003-11-20 Schering Corp., Kenilworth Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection

Also Published As

Publication number Publication date
IL139220A (en) 2013-02-28
NO20005755D0 (no) 2000-11-14
HU230432B1 (hu) 2016-06-28
EP0956861B1 (en) 2002-04-24
AU2005220271A1 (en) 2005-11-03
EP0956861A1 (en) 1999-11-17
AU766597B2 (en) 2003-10-16
ES2172288T3 (es) 2002-09-16
WO1999059621A1 (en) 1999-11-25
TWI277424B (en) 2007-04-01
ATE216591T1 (de) 2002-05-15
HUP0103423A2 (hu) 2002-01-28
SK17102000A3 (sk) 2001-05-10
DK0956861T3 (da) 2002-07-01
PT956861E (pt) 2002-08-30
AU3860099A (en) 1999-12-06
EP1213029A1 (en) 2002-06-12
DE69901321T2 (de) 2002-12-12
CN1230198C (zh) 2005-12-07
DE69901321D1 (de) 2002-05-29
CZ300540B6 (cs) 2009-06-10
CZ20004177A3 (cs) 2001-04-11
KR100694345B1 (ko) 2007-03-12
EP2305287A1 (en) 2011-04-06
JP5281726B2 (ja) 2013-09-04
MY129244A (en) 2007-03-30
NZ507621A (en) 2002-11-26
KR20010043624A (ko) 2001-05-25
SK288038B6 (en) 2013-01-02
AR019551A1 (es) 2002-02-27
IL207259A0 (en) 2010-12-30
AU2005220271B2 (en) 2005-11-03
JP2011173898A (ja) 2011-09-08
NO330715B1 (no) 2011-06-20
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
JP2002515453A (ja) 2002-05-28
AU2005220271B8 (en) 2010-11-18
HUP0103423A3 (en) 2003-11-28
CA2331823A1 (en) 1999-11-25
HK1021131A1 (en) 2000-06-02
NO20005755L (no) 2001-01-12
IL207259A (en) 2016-08-31
BR9910505A (pt) 2001-01-02

Similar Documents

Publication Publication Date Title
IL139220A0 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
IL134428A0 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
PL344794A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
HU9503751D0 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
EP0818976A4 (en) DISPOSABLE MASK AND SUCTION CATHETER
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
PL311031A1 (en) Use of concentrates comprising vwf in complex therapy in case of treatment by using anticoagulants and fibrinolitic drugs
IL92161A0 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
EP1224939A4 (en) INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
AU3857389A (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
HUP0200731A3 (en) Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
EP1908477A3 (en) Combination of temozolomide and pegylated interferon-alpha for treating cancer
GB9725480D0 (en) Cytokines and their use in the treatment of established chronic infections and cancers
HK1035906A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU8086498A (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiencyvirus infection
GB8901034D0 (en) Improvements in and relating to suction treatment of the body